GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Autodesk, Inc. (ADSK) [hlAlert]

Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small
molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson?s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.
( Total: 32 Current Stock Recommendations )
Autodesk, Inc.   (32)
Sell Hold 34% Buy 59%
Related companies
Cognizant ...   (31)
Hold 19% Buy 81%
Microsoft ...   (56)
Sell Hold 18% Buy 80%
Adobe Systems ...   (42)
Sell Hold 26% Buy 67%
Ca Inc.   (20)
Sell Hold 45% Buy 45%
Check Point ...   (38)
Hold 37% Buy 63%
Oracle Corp   (52)
Sell Hold 29% Buy 67%
Salesforce.com Inc   (60)
Sell Hold 20% Buy 77%
Symantec Corporation   (43)
Sell Hold 56% Buy 40%
Red Hat Inc.   (40)
Hold 35% Buy 65%
Sap ...   (35)
Sell Hold 34% Buy 51%
Filter by Gains:   
  
Rating:
Buy ADSK
up 35.09 %

Rating:
Hold ADSK
up 37.20 %

Rating:
Hold ADSK
up 41.91 %

Rating:
Buy ADSK
up 37.20 %

Rating:
Buy ADSK
up 41.91 %
Autodesk, Inc. (ADSK) rated Buy with price target $56 by UBS
Wednesday,  Sep 30, 2015  12:25 PM ET

Rating:
Buy ADSK
up 10.05 %

Rating:
Buy ADSK
up 84.50 %
Autodesk, Inc. (ADSK) rated Buy with price target $60 by UBS
Friday,  Aug 28, 2015  11:25 AM ET

Rating:
Buy ADSK
up 35.09 %

Rating:
Buy ADSK
down 12.83 %

Rating:
Buy ADSK
down 22.94 %

Rating:
Buy ADSK
up 34.12 %

Rating:
Buy ADSK
down 18.27 %

Rating:
Buy ADSK
up 84.50 %
Autodesk, Inc. (ADSK) rated Buy with price target $65 by UBS
Friday,  Aug 15, 2014  12:00 AM ET

Rating:
Buy ADSK
up 35.09 %

Rating:
Buy ADSK
down 8.47 %

Your Recent Stocks
SymbolLastChange
ADSK 60.55 up  21.10 %

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy